UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The global state of psoriasis disease epidemiology: a workshop report

British journal of dermatology (1951), 2017-07, Vol.177 (1), p.e4-e7

2017

Volltextzugriff (PDF)

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.674-681

2018

Volltextzugriff (PDF)

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review

Journal of the European Academy of Dermatology and Venereology, 2020-07, Vol.34 (7), p.1440-1448

2020

Volltextzugriff (PDF)

The role of the microbiome in psoriasis: moving from disease description to treatment selection?

British journal of dermatology (1951), 2018-05, Vol.178 (5), p.1020-1027

2018

Volltextzugriff (PDF)

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease

British journal of dermatology (1951), 2021-09, Vol.185 (3), p.646-648

2021

Volltextzugriff (PDF)

Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin‐17

British journal of dermatology (1951), 2018-06, Vol.178 (6), p.1364-1372

2018

Volltextzugriff (PDF)

The 2016 International League of Dermatological Societies' revised glossary for the description of cutaneous lesions

British journal of dermatology (1951), 2016-06, Vol.174 (6), p.1351-1358

2016

Volltextzugriff (PDF)

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives

British journal of dermatology (1951), 2012-03, Vol.166 (3), p.545-554

2012

Volltextzugriff (PDF)

Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.404-406

2020

Volltextzugriff (PDF)

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks

British journal of dermatology (1951), 2005-04, Vol.152 (4), p.597-615

2005

Volltextzugriff (PDF)

A classification of psoriasis vulgaris according to phenotype

British journal of dermatology (1951), 2007-02, Vol.156 (2), p.258-262

2007

Volltextzugriff (PDF)

A temporal analysis of the central neural processing of itch

British journal of dermatology (1951), 2012-05, Vol.166 (5), p.994-1001

2012

Volltextzugriff (PDF)

Ciclosporin in psoriasis clinical practice: an international consensus statement

British journal of dermatology (1951), 2004-05, Vol.150 (s67), p.11-23

2004

Volltextzugriff (PDF)

Biologics for psoriasis: current evidence and future use: Editorial

British journal of dermatology (1951), 2012-11, Vol.167, p.1-2

Griffiths, C.E.M.

2012

Volltextzugriff (PDF)

Update on the use of ciclosporin in immune-mediated dermatoses

British journal of dermatology (1951), 2006-07, Vol.155 (s2), p.1-16

2006

Volltextzugriff (PDF)

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.294-302

2020

Volltextzugriff (PDF)

Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID‐19 pandemic

British journal of dermatology (1951), 2020-10, Vol.183 (4), p.792-794

2020

Volltextzugriff (PDF)

Professor Lionel Fry (1933–2021)

British journal of dermatology (1951), 2021-07, Vol.185 (1), p.237-238

Griffiths, C.E.M.

2021

Volltextzugriff (PDF)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1047-1058

2021

Volltextzugriff (PDF)

适用于斑块状银屑病的 risankizumab 与 ustekinumab:严格评读

British journal of dermatology (1951), 2019-06, Vol.180 (6)

2019

Volltextzugriff (PDF)

The promise and challenges of cell therapy for psoriasis

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.887-898

2021

Volltextzugriff (PDF)

Risk of hospitalization and death due to infection in people with psoriasis: a population‐based cohort study using the Clinical Practice Research Datalink

British journal of dermatology (1951), 2021-01, Vol.184 (1), p.78-86

2021

Volltextzugriff (PDF)

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.935-944

2021

Volltextzugriff (PDF)

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

British journal of dermatology (1951), 2018-01, Vol.178 (1), p.132-139

2018

Volltextzugriff (PDF)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1124-1134

2021

Volltextzugriff (PDF)

1 – 25 von 233

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(227)
Mit Volltextzugriff
(229)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Dermatology
(123)
Life Sciences & Biomedicine
(120)
Science & Technology
(120)
Humans
(82)
Psoriasis
(68)
Biological And Medical Sciences
(34)
Medical Sciences
(33)
Psoriasis - Drug Therapy
(28)
Patients
(19)
Quality Of Life
(18)
Skin
(18)
Psoriasis. Parapsoriasis. Lichen
(16)
Monoclonal Antibodies
(15)
Treatment Outcome
(13)
Skin Diseases
(12)
Severity Of Illness Index
(11)
Immunotherapy
(10)
Psoriasis - Therapy
(10)
Clinical Trials
(9)
Dermatologic Agents - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The global state of psoriasis disease epidemiology: a workshop report

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review

The role of the microbiome in psoriasis: moving from disease description to treatment selection?

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease

Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin‐17

The 2016 International League of Dermatological Societies' revised glossary for the description of cutaneous lesions

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives

Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks

A classification of psoriasis vulgaris according to phenotype

A temporal analysis of the central neural processing of itch

Ciclosporin in psoriasis clinical practice: an international consensus statement

Biologics for psoriasis: current evidence and future use: Editorial

Update on the use of ciclosporin in immune-mediated dermatoses

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID‐19 pandemic

Professor Lionel Fry (1933–2021)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

适用于斑块状银屑病的 risankizumab 与 ustekinumab:严格评读

The promise and challenges of cell therapy for psoriasis

Risk of hospitalization and death due to infection in people with psoriasis: a population‐based cohort study using the Clinical Practice Research Datalink

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

Aktive Filter

Suchergebnisse filtern